Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOX for 4 Months vs 6 Months as Adjuvant Chemotherapy in Gastric Cancer
NCT03399110Phase 3Completed
- Sponsor
- Fudan University
- Start
- Jan 2018
- Primary completion
- Aug 2026
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine, oxaliplatin in gastric cancer (GC), sponsored by Fudan University. Started Jan 2018; status: completed.
02
Drugs
capecitabineoxaliplatin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT03399110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03399110.